Evidence map›Paper›PMID 34396128›Full record

ArticleNeuro-oncology advances

Descriptive and retrospective analysis of diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the pandemic.

Fernando Lozano-Sanchez, Renata Ursu, Anna Luisa Di-Stefano, Francois Ducray, Nadia Younan, Mehdi Touat, Matthieu Groh, Hanane Agguini, Catherine Belin, Luois Garnier and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fernando Lozano-SanchezService Neurology 2 - Mazarin, Assistance Public-Hôpitaux de Paris, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Sorbonne University, Paris, France.
Renata UrsuDepartment of Neurology, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris University, Paris, France.
Anna Luisa Di-StefanoDepartment of Neurology, Foch Hospital, Suresnes, Paris,France.
Francois DucrayCancerology Research Center of Lyon, INSERM U1052, CNRS UMR 5286, Cancer Cell Plasticity department, Transcriptome Diversity in Stem Cells laboratory, Lyon, France.
Nadia YounanService Neurology 2 - Mazarin, Assistance Public-Hôpitaux de Paris, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Sorbonne University, Paris, France.
Mehdi TouatService Neurology 2 - Mazarin, Assistance Public-Hôpitaux de Paris, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Sorbonne University, Paris, France.
Matthieu GrohDepartment of Internal Medicine, Foch Hospital, F-92151 Suresnes, France.
Hanane AgguiniDepartment of Neurology, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris University, Paris, France.
Catherine BelinDepartment of Neurology, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris University, Paris, France.
Luois GarnierCancerology Research Center of Lyon, INSERM U1052, CNRS UMR 5286, Cancer Cell Plasticity department, Transcriptome Diversity in Stem Cells laboratory, Lyon, France.
Jean-Yves DelattreService Neurology 2 - Mazarin, Assistance Public-Hôpitaux de Paris, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Sorbonne University, Paris, France.
Antoine CarpentierDepartment of Neurology, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris University, Paris, France.
Ahmed IdbaihService Neurology 2 - Mazarin, Assistance Public-Hôpitaux de Paris, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Sorbonne University, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLittle is known about diffuse glioma patients infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).

methodsWe performed a descriptive and retrospective analysis of 41 diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the COVID-19 pandemic.

resultsConfusion with or without fever was the most common neurological symptom (32%) supporting SARS-CoV2 testing in glioma patients with acute and unexplained confusion. Sixteen patients (39%) died after a median delay of 13 days. While multiple clinical, biological, and pathological features, COVID-19- or diffuse glioma-related, at hospital admission appeared to have a pejorative prognostic impact, none was significantly associated with death. Oncological treatments were interrupted at COVID-19 diagnosis and re-initiated with a median delay of 30 days after the end of COVID-19 symptoms.

conclusionsInterestingly, our retrospective study describes for the first time the characteristics of a cohort of diffuse glioma patients with symptomatic COVID-19. Diffuse glioma patients with poorly symptomatic COVID-19 did not come to the attention of physicians and were not enrolled in the study skewing the denominator for prognostic analysis. Further studies are warranted to specify prognosis of overall population of diffuse glioma patients with COVID-19, including asymptomatic patients, and interactions of prognostic factors of both COVID-19 and diffuse gliomas.

Indexed as

COVID-19diffuse gliomaoutcomeprognosisSARS-CoV2

Identifiers

PMID34396128
PMCPMC8360904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.